摘要
目的探讨凝血酶激活的纤溶抑制物活性(TAFI:A)和凝血酶-抗凝血酶复合物(TAT)水平与不同分期胃癌之间的关系。方法收集48例临床胃癌患者、34例同期住院的胃良性疾病患者和50名健康体检者的血液标本,采用发色底物法检测血浆中TAFI水平;ELISA法检测TAT水平;同时检测D-二聚体、纤维蛋白原,分析以上指标在不同分期胃癌的水平。通过受试者工作特征曲线(ROC曲线)分别评价TAFI和TAT的检验效能和最佳诊断分界值。结果与健康对照组及胃良性疾病组相比,胃癌病例组血浆TAFI、TAT、D-二聚体及纤维蛋白原水平均显著升高(P<0.05);胃良性疾病组与健康对照组上述指标的差异则无统计学意义(P>0.05)。血浆TAFI水平为28.85μg/mL时,灵敏度和特异性分别是0.646和0.869;TAT水平为31.50 ng/mL时,灵敏度和特异性分别是0.813和0.786。结论胃癌患者血浆TAFI和TAT水平显著升高是胃癌患者血栓形成倾向的标志,TAFI和TAT有望成为胃癌患病风险的预测指标。
Objective To explore the correlation between different stages of gastric cancer and the levels of thrombin- activated fibrinolysis inhibitor （TAFI） and thrombin-antithrombin （TAT）. Methods Blood samples were collected from 48 patients with gastric cancer （gastric cancer group）, 34 patients with benign gastric disorders （benign gastric disorder group）, and 50 healthy individuals （healthy control group）. Plasma levels of TAFI, TAT, D-D and fibrino- gen were measured using a chromogenic substrate method and ELISA. Then their correlations with different stages of gastric cancer were analyzed. The power of test and the best diagnostic value of TAFI and TAT were evaluated with receiver operating characteristic curve （ ROC curve）. Results Compared with healthy control group and benign gastric disorder group, the gastric cancer group had higher TAFI, D-D, fibrinogen, and TAT levels （ P 〈 0.05 ）. When TAFI level was 28.85 μg/mL, the sensitivity and specificity was 0.646 and 0. 869, respectively. When TAT level was 31.50 ng/mL, the sensitivity and specificity was 0. 813 and 0. 786, respectively. Conclusion Patients with gastric cancer have significantly higher TAFI and TAT levels. TAFI and TAT are indicators of thrombosis tendency, which can be used to evaluate the risk of gastric cancer.
出处
《山东大学学报（医学版）》
CAS
北大核心
2014年第2期73-77,共5页
Journal of Shandong University:Health Sciences
基金
济南市高校自主创新计划(201303048)
